表紙
市場調査レポート

MediPoint:神経血管インターベンション - EU市場の分析と予測

MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts

発行 GlobalData 商品コード 301168
出版日 ページ情報 英文 350 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
MediPoint:神経血管インターベンション - EU市場の分析と予測 MediPoint: Neurovascular Interventions - EU Analysis and Market Forecasts
出版日: 2014年04月30日 ページ情報: 英文 350 Pages
概要

世界の神経血管インターベンションは巨大で、2桁台の急速な速度で成長しています。神経血管インターベンション部門の急速な発展や低侵襲性治療技術の進歩により、将来的に治療可能となる疾患の分野が広がりつつあります。神経血管インターベンションの市場は、血管閉塞・血管再生・機械的血栓除去・アクセス/サポートの4つの分野に分かれています。

当レポートでは、EU5カ国における脳血管疾患(頭蓋内動脈瘤/動静脈奇形、アテローム性動脈硬化など)治療用の神経血管インターベンション市場について分析し、疾患の概要や市場構造、現在のアンメットニーズ、主な市場促進・抑制要因、今後の市場機会、現在治験中の主要製品、EU5カ国における市場動向(過去3年間の実績値と今後7年間の予測値)、製品カテゴリー別の詳細動向、主要企業のプロファイルなどを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 臨床転帰

  • 疾患の管理
    • 頭蓋内動脈瘤
    • 頭蓋内動静脈奇形
    • 硬膜動静脈瘻
    • 頭蓋内/頭蓋外アテローム性動脈硬化
    • 脳卒中
  • 治療方式
    • 概要
    • 医薬/化学療法
    • 外科療法
    • 血管内療法

第4章 産業の概要

  • 概況
  • 処置の傾向
    • 頭蓋内動脈瘤
    • 頭蓋内動静脈奇形
    • アテローム性動脈硬化
    • 急性虚血発作
  • 市場へのアクセス
    • 規制のプロセス
    • 医師の認識・意思決定プロセス
    • 臨床診療のバリエーション
    • 臨床データの不足
    • 地域レベルでの管理
    • コストの考慮
    • 医療費償還の傾向
  • 規制の問題/リコール
    • 規制の問題
  • 企業合併・買収(M&A)/主なパートナーシップ
  • 経済的な影響
    • 頭蓋内動脈瘤/動静脈奇形の場合
    • 脳卒中の場合
  • 第5章 アンメットニーズ
  • 概要
  • 訓練・実績・医師向け訓練ガイドラインのニーズ
  • 臨床データの不足
  • 急性虚血発作の管理の改善
  • 外科療法の複雑化への対処
  • クリッピング術の課題への対処
  • 未破裂頭蓋内動脈瘤の最適な治療戦略の欠如
  • 複雑な形態・規模の動脈瘤に対する効果的な治療法の必要性
  • 頭蓋内動静脈奇形の治療の難しさ
  • バルーン血管形成法に関する課題への対処
  • 神経血管ステントに関する課題への対処
  • 二重抗血小板療法(DAPT)の複雑化
  • 医薬療法の改善の必要性
  • アクセス緩和の必要性

第6章 市場機会の分析

  • 神経血管インターベンション市場
  • 神経インターベンション装置の設計改善
  • 複雑な頭蓋内動脈瘤/動静脈奇形の治療に関する課題
  • 多数の患者を対象とした治療法
  • 急性虚血発作の患者の治療法の最適化
  • 薬剤溶出デバイスの開発
  • 新興市場

第7章 市場促進要因と課題

  • 市場促進要因
    • 疾患の有病率の上昇
    • 血管内コイルによる臨床転帰の改善
    • ステント/バルーン支援下コイリングによる治療法の改変
    • 複雑頭蓋内動脈瘤の実行可能な治療オプション
    • 動脈瘤治療のための、コイル以外の代替的な閉塞形成装置
    • 頭蓋内動静脈奇形における血管内閉塞
    • 頭蓋内動静脈奇形治療のための画像診断
    • 頸動脈硬化性疾患のためのステント
    • 低プロファイルのステント装置
    • 機械的血栓除去装置の最疎通率の改善
    • コスト抑制
    • 長期的・コスト効率的なデータ入手の可能性
  • 市場の課題
    • 神経インターベンション処置・装置の複雑性
    • 臨床データの不足
    • 治療費の高さ
    • 医療費償還額の不足
    • 生理活性/被覆コイルの優位性の欠如
    • 脳卒中治療の代替的方法
    • 規制上の問題:米国FDAとECマーク
    • 医療費抑制の動きと医療費償還
    • ベンチャーキャピタルの利用可能性
    • 医療機器への物品税

第8章 競争力の評価

  • 概要
  • EU5カ国における市場シェア
  • 上市済み製品(計29製品)

第9章 パイプライン製品の評価

  • 概要
  • 開発段階別のパイプライン製品
  • 製品のプロファイル(計12製品)

第10章 治験の分析

  • 概要
  • 注目すべき治験
    • 血管閉塞
    • 血流迂回
    • 血管再生
    • 機械的血栓除去

第11章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル(計30社分)

第12章 市場の将来展望

  • 概要
  • 国別市場の見通し
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国

第13章 付録

図表一覧

目次
Product Code: GDME1098CFR

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

The neurovascular interventions market in the 5EU is a vast and dynamic market that consists of innovative and emerging technologies. Neurointerventional devices can be used to treat a variety of cerebrovascular indications such as intracranial aneurysms, AVMs, and dural AVFs, atherosclerotic disease, and stroke. In this report, the neurointerventional market encompasses embolization, revascularization, mechanical thrombectomy, and access/support devices.

Scope

  • An overview of Neurovascular, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the EU Neurovascular market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Neurovascular.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Neurovascular sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the EU Neurovascular market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the EU Neurovascular market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the EU Neurovascular market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Clinical Outcomes

  • 3.1. Disease Management
    • 3.1.1. Intracranial Aneurysms
    • 3.1.2. Intracranial Arteriovenous Malformations
    • 3.1.3. Dural Arteriovenous Fistulas
    • 3.1.4. Intracranial and Extracranial Atherosclerotic Disease
    • 3.1.5. Stroke
  • 3.2. Treatment Modalities
    • 3.2.1. Overview
    • 3.2.2. Medical/Chemical Therapy
    • 3.2.3. Surgical Therapy
    • 3.2.4. Endovascular Therapy

4. Industry Overview

  • 4.1. Overview
  • 4.2. Procedure Trends
    • 4.2.1. Intracranial Aneurysms
    • 4.2.2. Intracranial Arteriovenous Malformations
    • 4.2.3. Atherosclerotic Disease
    • 4.2.4. Acute Ischemic Stroke
  • 4.3. Market Access
    • 4.3.1. Regulatory Process
    • 4.3.2. Physician Perception and Decision Making Process
    • 4.3.3. Variations in Clinical Practice
    • 4.3.4. Lack of Clinical Data
    • 4.3.5. Regional-Level Control
    • 4.3.6. Cost-Considerations
    • 4.3.7. Reimbursement Trends
  • 4.4. Regulatory Issues/Recalls
    • 4.4.1. Regulatory Issues
  • 4.5. Mergers and Acquisitions/Key Partnerships
    • 4.5.1. Covidien and Nfocus Neuromedical
    • 4.5.2. Stryker Corporation and Surpass Medical
    • 4.5.3. Covidien and MindFrame
    • 4.5.4. Covidien and Reverse Medical Corporation
    • 4.5.5. Stryker Corporation and Boston Scientific Neurovascular
    • 4.5.6. Stryker Corporation and Concentric Medical
    • 4.5.7. Covidien and ev3
    • 4.5.8. Medtronic and Invatec
    • 4.5.9. Johnson & Johnson and Micrus Endovascular
    • 4.5.10. ev3 and Chestnut Medical Technologies
    • 4.5.11. Boston Scientific Corporation and Guidant Corporation
  • 4.6. Economic Impact
    • 4.6.1. Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations
    • 4.6.2. Economic Impact of Stroke

5. Unmet Needs

  • 5.1. Overview
  • 5.2. Need for Practice, Performance, and Physician Training Guidelines
  • 5.3. Lack of Clinical Data
  • 5.4. Improve Management of Acute Ischemic Stroke
  • 5.5. Address Complications of Surgical Therapy
  • 5.6. Addressing the Challenges of Surgical Clipping
  • 5.7. Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms
  • 5.8. Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes
  • 5.9. Difficulty in Treating Intracranial Arteriovenous Malformations
  • 5.10. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.11. Addressing Challenges of Neurovascular Stenting
    • 5.11.1. Risk of Post-Procedural Complications
    • 5.11.2. In-Stent Restenosis
    • 5.11.3. Stent Navigation
  • 5.12. Complications of Dual Antiplatelet Therapy
  • 5.13. Need to Improve Medical Therapy
  • 5.14. Improve Ease of Access

6. Market Opportunity Analysis

  • 6.1. Neurovascular Interventions Market
  • 6.2. Improve Neurointerventional Device Design
  • 6.3. Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations
    • 6.3.1. Intracranial Aneurysms
    • 6.3.2. Intracranial Arteriovenous Malformations
  • 6.4. Target Challenging Patient Populations
  • 6.5. Optimize Care for Acute Ischemic Stroke Patients
  • 6.6. Development of Drug-Eluting Devices
  • 6.7. Emerging Markets

7. Market Drivers and Barriers

  • 7.1. Market Drivers
    • 7.1.1. Rising Prevalence of Disease
    • 7.1.2. Improved Clinical Outcomes with Endovascular Coiling
    • 7.1.3. Remodeling Techniques with Stent and Balloon-Assisted Coiling
    • 7.1.4. Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms
    • 7.1.5. Alternative Non-Coiling Embolization Devices for Aneurysm Treatment
    • 7.1.6. Endovascular Embolization of Intracranial Arteriovenous Malformations
    • 7.1.7. Imaging Assessment for Intracranial Arteriovenous Malformation Treatment
    • 7.1.8. Stenting for Carotid Atherosclerotic Disease
    • 7.1.9. Low-Profile Stent Systems
    • 7.1.10. Improved Recanalization Rates with Mechanical Thrombectomy Devices
    • 7.1.11. Cost Savings
    • 7.1.12. Availability of Long-Term and Cost-Effective Data
  • 7.2. Market Barriers
    • 7.2.1. Complications of Neurointerventional Procedures and Devices
    • 7.2.2. Lack of Clinical Data
    • 7.2.3. High Cost of Treatment
    • 7.2.4. Lack of Reimbursement
    • 7.2.5. Lack of Superiority of Bioactive/Coated Coils
    • 7.2.6. Alternative Technologies for Stroke Therapy
    • 7.2.7. Regulatory Challenges: US Food and Drug Administration and European Conformity Mark
    • 7.2.8. Healthcare Cost-Cutting and Reimbursement
    • 7.2.9. Availability of Venture Capital
    • 7.2.10. Medical Device Excise Tax

8. Competitive Assessment

  • 8.1. Overview
  • 8.2. 5EU Market Share
  • 8.3. Marketed Products
    • 8.3.1. Aachen Resonance
    • 8.3.2. Abbott Vascular
    • 8.3.3. Acandis
    • 8.3.4. B. Braun
    • 8.3.5. BALT Extrusion
    • 8.3.6. Blockade Medical
    • 8.3.7. Boston Scientific Corporation
    • 8.3.8. Contego Medical
    • 8.3.9. Cook Medical
    • 8.3.10. Covidien
    • 8.3.11. Gardia Medical
    • 8.3.12. Gore Medical
    • 8.3.13. InspireMD
    • 8.3.14. ITGI Medical
    • 8.3.15. Johnson & Johnson
    • 8.3.16. Medikit
    • 8.3.17. Medtronic
    • 8.3.18. Merlin MD
    • 8.3.19. MicroPort Scientific Corporation
    • 8.3.20. Minvasys
    • 8.3.21. Neuravi
    • 8.3.22. Optimed
    • 8.3.23. Penumbra
    • 8.3.24. Phenox GmbH
    • 8.3.25. Reverse Medical
    • 8.3.26. Sequent Medical
    • 8.3.27. Stryker Neurovascular Intervention
    • 8.3.28. Terumo Corporation
    • 8.3.29. Valor Medical

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Pipeline by Stage of Development
  • 9.3. Product Profiles
    • 9.3.1. Aneurysm Occlusion Saddle
    • 9.3.2. Ballstent Microcatheter
    • 9.3.3. Blood Clot Removing Device
    • 9.3.4. EKOS' EkoSonic Small Vessel Endovascular System
    • 9.3.5. Flow-Diverting Thin-Film Nitinol Covered Stent
    • 9.3.6. Ischemic Stroke System
    • 9.3.7. Janjua Aneurysm Net
    • 9.3.8. Multilayer Aneurysm Repair System
    • 9.3.9. NAVIMAX
    • 9.3.10. Palmaz Scientific Stents
    • 9.3.11. Silk Road System
    • 9.3.12. Transcranial Thrombectomy Catheter

10. Clinical Trial Analysis

  • 10.1. Overview
  • 10.2. Clinical Trials to Watch
    • 10.2.1. Embolization
    • 10.2.2. Flow Diversion
    • 10.2.3. Revascularization
    • 10.2.4. Mechanical Thrombectomy

11. Current and Future Players

  • 11.1. Overview
  • 11.2. Trends in Corporate Strategy
  • 11.3. Company Profiles
    • 11.3.1. BALT Extrusion
    • 11.3.2. Covidien
    • 11.3.3. Johnson & Johnson
    • 11.3.4. Penumbra
    • 11.3.5. Stryker Corporation
    • 11.3.6. Terumo Corporation
    • 11.3.7. Abbott Vascular
    • 11.3.8. Boston Scientific Corporation
    • 11.3.9. Cook Medical
    • 11.3.10. Gore Medical
    • 11.3.11. Medtronic
    • 11.3.12. Aachen Resonance
    • 11.3.13. Acandis
    • 11.3.14. B. Braun
    • 11.3.15. Blockade Medical
    • 11.3.16. Contego Medical
    • 11.3.17. Gardia Medical
    • 11.3.18. InspireMD
    • 11.3.19. ITGI Medical
    • 11.3.20. Medikit
    • 11.3.21. Merlin MD
    • 11.3.22. MicroPort Scientific Corporation
    • 11.3.23. Minvasys
    • 11.3.24. Neuravi
    • 11.3.25. Optimed
    • 11.3.26. Phenox GmBH
    • 11.3.27. Reverse Medical
    • 11.3.28. Sequent Medical
    • 11.3.29. Valor Medical
    • 11.3.30. Other Companies

12. Market Outlooks

  • 12.1. Overview
  • 12.2. Country-Specific Market Outlook
    • 12.2.1. France
    • 12.2.2. Germany
    • 12.2.3. Italy
    • 12.2.4. Spain
    • 12.2.5. United Kingdom

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
  • 13.4. Physicians and Specialists Included in this Study
    • 13.4.1. Vivek Gupta, MD
    • 13.4.2. Zsolt Kulscar, MD, PhD
    • 13.4.3. Salvatore Mangiafico, MD
    • 13.4.4. Thanh Nguyen, MD, FRCPc
    • 13.4.5. Eduardo Wajnberg, MD
    • 13.4.6. Phil White, MD
    • 13.4.7. Osama O Zaidat, MD, MS, FAAN, FAHA
  • 13.5. Primary Research
    • 13.5.1. Primary Research - Key Opinion Leader Interviews
    • 13.5.2. Expert Panel Validation
  • 13.6. Forecasting Methodology
  • 13.7. About the Authors
    • 13.7.1. Analysts
    • 13.7.2. Global Head of Healthcare
  • 13.8. About MediPoint
  • 13.9. About GlobalData
  • 13.10. Disclaimer

List of Tables

  • Table 1: Complications of Cerebral Artery Bypass Surgery
  • Table 2: Types of Cerebral Embolic Protection Devices
  • Table 3: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 4: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 5: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 6: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 7: Acandis Neurovascular Intervention Marketed Products
  • Table 8: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 9: B. Braun Neurovascular Intervention Marketed Product
  • Table 10: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 11: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 12: BALT Extrusion Neurovascular Intervention Marketed Access Products
  • Table 13: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 14: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 15: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 16: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 17: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 18: Contego Medical Neurovascular Intervention Marketed Product
  • Table 19: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 20: Cook Medical Neurovascular Intervention Marketed Products
  • Table 21: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 22: Covidien Neurovascular Interventional Marketed Products
  • Table 23: Covidien Neurovascular Intervention Marketed Access Products
  • Table 24: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 25: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 26: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 27: Gore Medical Neurovascular Intervention Marketed Products
  • Table 28: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 29: InspireMD Neurovascular Intervention Marketed Product
  • Table 30: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 31: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 32: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 33: Codman Neurovascular Marketed Embolization Products
  • Table 34: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products
  • Table 35: Codman Neurovascular's (Codman & Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 36: Cordis Corporation Marketed Neurointerventional Products
  • Table 37: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 38: Medikit Neurovascular Intervention Marketed Products
  • Table 39: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 40: Medtronic Neurovascular Intervention Marketed Products
  • Table 41: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 42: Merlin MD Neurovascular Intervention Marketed Product
  • Table 43: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 44: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 45: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 46: Minvasys Neurovascular Intervention Marketed Product
  • Table 47: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 48: Neuravi Neurovascular Intervention Marketed Product
  • Table 49: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 50: Optimed Neurovascular Intervention Marketed Products
  • Table 51: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 52: Penumbra Neurovascular Intervention Marketed Products
  • Table 53: Penumbra Marketed Neurovascular Access Products
  • Table 54: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 55: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 56: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 57: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 58: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 59: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 60: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 61: Stryker Neurovascular Intervention Marketed Products
  • Table 62: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products
  • Table 63: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 64: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products
  • Table 65: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 66: MicroVention Neurovascular Intervention Marketed Products
  • Table 67: MicroVention Marketed Neurovascular Access Products
  • Table 68: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 69: Valor Medical Neurovascular Intervention Marketed Products
  • Table 70: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 71: Global Neurovascular Interventions Pipeline Products
  • Table 72: Aneurysm Occlusion Saddle SWOT Analysis, 2014
  • Table 73: EKOS EkoSonic SV System SWOT Analysis, 2014
  • Table 74: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014
  • Table 75: Janjua Aneurysm Net SWOT Analysis, 2014
  • Table 76: Multilayer Aneurysm Repair System SWOT Analysis, 2014
  • Table 77: NAVIMAX SWOT Analysis, 2014
  • Table 78: Palmaz Scientific Stents SWOT Analysis, 2014
  • Table 79: Silk Road System SWOT Analysis, 2014
  • Table 80: BALT Extrusion Company Profile
  • Table 81: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 82: BALT Extrusion SWOT Analysis, 2014
  • Table 83: Covidien Company Profile
  • Table 84: Covidien Neurovascular Intervention Marketed Products
  • Table 85: Covidien SWOT Analysis, 2014
  • Table 86: Codman & Shurtleff Company Profile
  • Table 87: Codman & Shurtleff Neurovascular Intervention Marketed Products
  • Table 88: Codman & Shurtleff SWOT Analysis, 2014
  • Table 89: Cordis Corporation Company Profile
  • Table 90: Cordis Corporation Neurovascular Intervention Marketed Products
  • Table 91: Cordis Corporation SWOT Analysis, 2014
  • Table 92: Penumbra Company Profile
  • Table 93: Penumbra Neurovascular Intervention Marketed Products
  • Table 94: Penumbra SWOT Analysis, 2014
  • Table 95: Stryker Corporation Company Profile
  • Table 96: Stryker Corporation Neurovascular Intervention Marketed Products
  • Table 97: Stryker Corporation SWOT Analysis, 2014
  • Table 98: Terumo Corporation Company Profile
  • Table 99: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products
  • Table 100: MicroVention Neurovascular Intervention Marketed Products
  • Table 101: Terumo Corporation SWOT Analysis, 2014
  • Table 102: Abbott Vascular Company Profile
  • Table 103: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 104: Abbott Vascular SWOT Analysis, 2014
  • Table 105: Boston Scientific Corporation Company Profile
  • Table 106: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 107: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 108: Cook Medical Company Profile
  • Table 109: Cook Medical Neurovascular Intervention Marketed Products
  • Table 110: Cook Medical SWOT Analysis, 2014
  • Table 111: Gore Medical Company Profile
  • Table 112: Gore Medical Neurovascular Intervention Marketed Products
  • Table 113: Gore Medical SWOT Analysis, 2014
  • Table 114: Medtronic Company Profile
  • Table 115: Medtronic Neurovascular Intervention Marketed Products
  • Table 116: Medtronic SWOT Analysis, 2014
  • Table 117: Aachen Resonance Company Profile
  • Table 118: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 119: Aachen Resonance SWOT Analysis, 2014
  • Table 120: Acandis Company Profile
  • Table 121: Acandis Neurovascular Intervention Marketed Products
  • Table 122: Acandis SWOT Analysis, 2014
  • Table 123: B. Braun Company Profile
  • Table 124: B. Braun Neurovascular Intervention Marketed Product
  • Table 125: B. Braun SWOT Analysis, 2014
  • Table 126: Blockade Medical Company Profile
  • Table 127: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 128: Blockade Medical SWOT Analysis, 2014
  • Table 129: Contego Medical Company Profile
  • Table 130: Contego Medical Neurovascular Intervention Marketed Product
  • Table 131: Contego Medical SWOT Analysis, 2014
  • Table 132: Gardia Medical Company Profile
  • Table 133: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 134: Gardia Medical SWOT Analysis, 2014
  • Table 135: InspireMD Company Profile
  • Table 136: InspireMD Neurovascular Intervention Marketed Product
  • Table 137: InspireMD SWOT Analysis, 2014
  • Table 138: ITGI Medical Company Profile
  • Table 139: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 140: ITGI Medical SWOT Analysis, 2014
  • Table 141: Medikit Company Profile
  • Table 142: Medikit Neurovascular Intervention Marketed Products
  • Table 143: Medikit SWOT Analysis, 2014
  • Table 144: Merlin MD Company Profile
  • Table 145: Merlin MD Neurovascular Intervention Marketed Product
  • Table 146: Merlin MD SWOT Analysis, 2014
  • Table 147: MicroPort Scientific Corporation Company Profile
  • Table 148: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 149: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 150: Minvasys Company Profile
  • Table 151: Minvasys Neurovascular Intervention Marketed Product
  • Table 152: Minvasys SWOT Analysis, 2014
  • Table 153: Neuravi Company Profile
  • Table 154: Neuravi Neurovascular Intervention Marketed Product
  • Table 155: Neuravi SWOT Analysis, 2014
  • Table 156: Optimed Company Profile
  • Table 157: Optimed Neurovascular Intervention Marketed Products
  • Table 158: Optimed SWOT Analysis, 2014
  • Table 159: Phenox GmBH Company Profile
  • Table 160: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 161: Phenox GmBH SWOT Analysis, 2014
  • Table 162: Reverse Medical Company Profile
  • Table 163: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 164: Reverse Medical SWOT Analysis, 2014
  • Table 165: Sequent Medical Company Profile
  • Table 166: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 167: Sequent Medical SWOT Analysis, 2014
  • Table 168: Valor Medical Company Profile
  • Table 169: Valor Medical Neurovascular Intervention Marketed Products
  • Table 170: Valor Medical SWOT Analysis, 2014
  • Table 171: Other Companies in the Neurovascular Intervention Market, 2014
  • Table 172: Neurovascular Interventions Market Sales ($m) Forecast for France, 2011-2020
  • Table 173: Neurovascular Interventions Market Sales ($m) Forecast for Germany, 2011-2020
  • Table 174: Neurovascular Interventions Market Sales ($m) Forecast for Italy, 2011-2020
  • Table 175: Neurovascular Interventions Market Sales ($m) Forecast for Spain, 2011-2020
  • Table 176: Neurovascular Interventions Market Sales ($m) Forecast for the UK, 2011-2020

List of Figures

  • Figure 1: Treatment Modalities - Neurovascular Interventions
  • Figure 2: Types of Stents Used for Neurovascular Interventions
  • Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, 5EU, 2011-2020
  • Figure 4: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, 5EU, 2011-2020
  • Figure 5: Revascularization Procedure Volume for Treating Atherosclerotic Disease, 5EU, 2011-2020
  • Figure 6: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, 5EU, 2011-2020
  • Figure 7: Neurointerventional Market Distribution, 5EU, 2013
  • Figure 8: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014
  • Figure 9: Neurovascular Interventions Market ($m) for Treating Cerebrovascular Disease, 5EU, 2011-2020
  • Figure 10: Distribution of Percentage of Patients Treated for Cerebrovascular Disease, 5EU, 2013
  • Figure 11: Neurovascular Interventions Market Revenue ($m), 5EU, 2013 and 2020
  • Figure 12: French Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 13: French Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 14: French Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 15: French Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 16: French Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 17: German Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 18: German Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 19: German Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 20: German Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 21: German Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 22: Italian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 23: Italian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 24: Italian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 25: Italian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 26: Italian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 27: Spanish Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 28: Spanish Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 29: Spanish Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 30: Spanish Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 31: Spanish Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 32: UK Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 33: UK Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 34: UK Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 35: UK Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 36: UK Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
Back to Top